Market
GLP-1 drug with highest US prescription increase by end of 2025?
2
Resolution / Starting Odds
Ozempic • 25%
Wegovy • 25%
Mounjaro • 25%
Other GLP-1 drug • 25%
Pharmaceutical sales and prescription data
Story
GLP-1 Drugs Like Ozempic, Wegovy Reduce Risk of 42 Conditions, Increase Risk of 19 Including Pancreatitis
Jan 20, 2025, 10:01 PM
A comprehensive study published in Nature Medicine has analyzed the health impacts of GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, on over 2 million diabetic patients. The research, conducted by scientists from Washington University and the Veterans Affairs St. Louis Health Care System, found that these drugs, primarily used for managing type 2 diabetes and obesity, are associated with a reduced risk of 42 health conditions. These include a 9% lower risk of heart attacks, an 8% reduced risk of dementia, and decreased risks of substance abuse, schizophrenia, and suicidal thoughts. However, the study also identified an increased risk for 19 conditions, including gastrointestinal issues, kidney stones, and a more than doubled risk of pancreatitis. The findings suggest that while GLP-1 agonists offer significant health benefits, they also come with notable risks that require careful monitoring.
View original story
Similar markets
Novo Nordisk • 25%
Eli Lilly • 25%
AstraZeneca • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Alzheimer's Disease • 25%
Other • 25%
Obesity • 25%
Type 2 Diabetes • 25%
Mounjaro • 25%
Ozempic • 25%
Other • 25%
Wegovy • 25%
Other • 25%
Olire • 25%
Ozempic • 25%
Lirux • 25%
Mixed findings • 25%
More benefits • 25%
More risks • 25%
No significant new findings • 25%
Divided opinion • 25%
No significant change • 25%
Less favorable • 25%
More favorable • 25%
More than 75% • 25%
50% to 75% • 25%
25% to 50% • 25%
Less than 25% • 25%
Increase coverage • 25%
Decrease coverage • 25%
No change • 25%
Other adjustments • 25%